Kaplan-Meier Curves of Overall Survival 
tumor, tumors
EVENTS, TUMOR, TUMORS
A, For all patients, those in the epirubicin plus paclitaxel (EP) group had 39 events; those in the epirubicin and cyclophosphamide followed by paclitaxel (EC-P) group, 38 events. B, For patients with luminal A tumors, patients in the EP group had 8 events; those in the EC-P group, 8 events. C, For patients with luminal B tumors, patients in the EP group had 24 events; those in the EC-P group, 27 events. HR indicates hazard ratio.There were 161 DDFS events during the follow-up period, of which 73 were in the EP group and 88 were in the EC-P group. The 5-year DDFS for the ITT population treated with EP or EC-P was 88.4% vs 84.5%, respectively (HR, 0.77 [95% CI, 0.57-1.05]) (eFigure 1 in In addition, there were 217 DFS-s events during the follow-up period, of which 105 were in the EP group and 112 were in the EC-P group. The 5-year DFS-s for ITT population treated with EC-P or EP was 83.9% vs 79.1%, respectively (HR, 0.87 [95% CI, 0.66-1.14]) (eFigure 2 in Subgroup analysis was stratified by age, menopausal status, subtype, tumor grade, Ki67 level, lymphovascular invasion, endocrine therapy, and radiotherapy (eTable 2 in 